Echo Therapeutics Inc., developer of non-invasive, wireless, transdermal glucose monitoring systems, today announced positive results of a clinical study of its new and improved biosensor, the Symphony tCGM System, for patients with type 1 and type 2 Diabetes.
The Symphony tCGM System consists of the company’s wireless transmission and transdermal biosensor technologies, as well as its Prelude SkinPrep System, which incorporates needle-free, controlled skin ablation.
The study tested the performance of the system in glucose readings in ten patients with type 1 or type 2 Diabetes; results showed a 97 percent accuracy in the readings.
“This study represents another major step forward in our Symphony development program,” Patrick Mooney, M.D., Echo chairman and CEO stated in the press release. “We believe that we have successfully developed a new cost-effective, one-piece biosensor and, with this study, we have demonstrated improvement in the accuracy of our Symphony system glucose readings. Data from this study demonstrates that Symphony, using the new, improved, cost-effective biosensor, is safe, accurate and reliable at monitoring glucose levels. We look forward to continued progress with our Symphony development program throughout this year and next as we move toward our goal of making Symphony available to patients.”
The news sent shares of ECTE soaring nearly 15 percent to $3.15 in today’s early trade.
For more information visit www.echotx.com
Let us hear your thoughts below: